We briefly touch upon some of the available information for upcoming drugs below, both in the US and abroad: Tern Pharmaceutical (TERN): TERN-601 TERN-601 is a preclinical GLP1R agonist , which in mice has been shown to be able to reduce food intake, slow gastric emptying and improve glucose tolerance
Given the substantial burden of CKD associated with T2D, an aggressive approach to treatment is required [10]
they are produced in smaller amounts by the intestines and neurons in the brain
This heightened risk is driven by several factors linked to diabetes: Accelerated Atherosclerosis: High blood glucose levels can damage the inner lining of the arteries (the endothelium), making them more susceptible to the buildup of fatty plaques
You might be surprised how much potassium you get from: Calcium helps blood vessels constrict and relax, explains Zumpano
, (LSM [95% ] : -1,68 [-1,91, -1,46] / -1,22 [-1,45, -1,00] /